Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002651 | 0.94 | LTB4R2 (0.53) | CNR2LTB4R2LTB4RALOX5 | |
| SCHEMBL3994210 | 0.91 | CNR2 (0.47) | CNR2LTB4R2LTB4RALOX5FFAR1 | |
| SCHEMBL4003245 | 0.86 | CYP1A2 (0.49) | CNR2LTB4R2LTB4RALOX5PPARA | |
| SCHEMBL3996328 | 0.86 | LTB4R2 (0.50) | CNR2LTB4R2LTB4RALOX5 | |
| SCHEMBL4001535 | 0.86 | CNR2 (0.49) | CNR2LTB4R2LTB4RALOX5 | |
| SCHEMBL4630064 | 0.85 | CNR2 (0.62) | CNR2LTB4R2ALOX5 | |
| SCHEMBL6220527 | 0.82 | NPC1 (0.50) | CNR2LTB4R2LTB4RALOX5 | |
| Tert-Butylamine SCHEMBL5312728 | 0.81 | CNR2 (0.57) | CNR2LTB4R2ALOX5 | |
| SCHEMBL4629865 | 0.80 | LTB4R2 (0.63) | CNR2LTB4R2 | |
| SCHEMBL4002675 | 0.80 | LTB4R2 (0.51) | CNR2LTB4R2LTB4RALOX5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521461-B2 | Benzoic acid derivatives as modulators of PPAR alpha and gamma | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | claimed |
| US-20050267149-A1 | Benzoic acid derivatives as modulators of ppar alpha and gamma | ASTRAZENECA AB (SE) | 2005-12-01 | — | — | US | claimed |
| US-7521461-B2 | Benzoic acid derivatives as modulators of PPAR alpha and gamma | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| US-20050267149-A1 | Benzoic acid derivatives as modulators of ppar alpha and gamma | ASTRAZENECA AB (SE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267149-A1 | Benzoic acid derivatives as modulators of ppar alpha and gamma | PPARG, NR4A1, NR0B1 | CNR2 48/4885LTB4R2 1032/4885LTB4R 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.